Prefilled Syringes Research Report 2020-2030: Insights by Therapeutic Area, Type of Syringe, Type of Material, Number of Chambers, Type of Drug Molecule and Key Geographies -

DUBLIN--()--The "Prefilled Syringes Market (5th Edition), 2020-2030" report has been added to's offering.

Prefilled Syringes Market (5th edition), 2019-2030 features an extensive study of the current market landscape of prefilled syringes and the likely future opportunities associated with such devices, over the next 10-12 years. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

One of the key objectives of the report was to evaluate the current market size and the future opportunity within the prefilled syringes market. Based on various relevant parameters, such as the number of commercialized combination products, annual adoption rate, and expected pricing, we have provided an informed estimate of the likely evolution of the market over the period 2019-2030.

In order to provide a detailed future outlook, our projections have been segmented on the basis of:

  • [A] therapeutic area (autoimmune disorders, infectious diseases, neurological disorders, blood disorders, oncological disorders, psychiatric disorders, respiratory disorders, cardiovascular disorders, metabolic disorders, ophthalmic diseases, orthopedic disorders and others),
  • [B] type of syringe,
  • [C] type of material (glass and plastic),
  • [D] number of chambers (single chamber and dual chamber),
  • [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and
  • [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)).

According to experts in the healthcare industry, one in three adults are estimated to be suffering from some type of chronic clinical condition, such as multiple sclerosis, diabetes, rheumatoid arthritis and cardiovascular diseases. Chronic clinical conditions are considered to be among the leading causes of death and disability across the world. Typically, in such cases, individuals are required to medicate on a daily basis. In addition to the cost of medication, such individuals are also burdened with a deteriorating quality of life, and often struggle with medication adherence.

According to the US Centers for Disease Control (CDC), the overall annual expense incurred by those living with chronic diseases is steadily growing and is currently estimated to be more than USD 3 trillion. The development and commercialization of self-administrable dosage forms of drugs indicated to treat chronic clinical conditions has made a significant positive impact not only on the healthcare expenses borne by patients but also on compliance to prescribed therapeutic regimens. As the number of patients suffering from such disorders increase, the demand for more convenient and patient-friendly drug delivery solutions is also on the rise.

Most self-injection devices/systems, such as autoinjectors and pen-injectors, rely on prefilled syringes, which serve as primary drug containers in the aforementioned products. Moreover, despite having been in the market for more than three decades now, the overall interest in prefilled syringes continues to grow. In fact, the recent increase in use of biologics, which are usually administered via parenteral routes, has had a significant impact on the demand for prefilled syringes. Over the years, significant improvements have been made to conventional prefilled syringes in order to further expand the scope of their applications. In this context, it is worth mentioning that dual/multi-chambered syringes designed for the administration of lyophilized drugs are already available in the market.

In such products, the syringe barrel is divided into two chambers, one of which contains the appropriate diluent for the prefilled (lyophilized) drug formulation. Likewise, there are multiple types of specialty syringes, including contrast agent containing syringes and flush syringes. Further, since the introduction and enforcement of the Needlestick Safety and Prevention Act in 2000, several medical device manufacturers have developed add-on or integrated safety devices for prefilled syringes. In fact, by 2020, the incorporation of safety features in prefilled syringes is anticipated to be made mandatory across the world. We are led to believe that the aforementioned developments are likely to fuel innovation and subsequent future growth in this market.

In addition to other elements, the study includes:

  • An overview of the current market landscape of companies engaged in manufacturing prefilled syringes, providing information on year of establishment, company size, geographical location of the headquarters and manufacturing facilities, type of material used (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume.
  • An overview of the current market landscape of companies that are developing drugs in combination with prefilled syringes, featuring information on year of establishment, company size, geographical location of the developers, target therapeutic area, phases of development, type of drug molecule, route of administration, approval year (for marketed products), dosage details (for marketed products) and other approved dosage forms (for marketed products).
  • A detailed competitiveness analysis of the various prefilled syringes that we came across, taking into consideration the supplier power (based on the employee size of developer/manufacturer and their respective annual revenues) and key product specifications, such as number of chambers in the barrel, number of needle systems, volume of the barrel, technological advancement/user-friendliness and other distinguishing features.
  • A list of marketed drugs/therapies and pipeline candidates that are likely to be developed in combination with prefilled syringes in the near future, shortlisted based on an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
  • An analysis presenting potential strategic partners (primarily drug developers) for prefilled syringe manufacturers (with regard to likely collaboration opportunities for combination product development) based on different parameters, such as pipeline strength, target therapeutic indication(s) and developer strength.
  • An analysis of the various prefilled syringe combination product-related initiatives of big pharma players, based on parameters, such as current adoption (based on number of approved and under development prefilled syringe combination products) and likely future adoption (based on potential injectable product candidates in the pipeline that are likely to be delivered via prefilled syringes), target therapeutic area(s) and type of drug molecule.
  • A review of the landscape of contract fill/finish services providers that offer services for prefilled syringes, featuring a list of active (large-sized) service providers and analysis based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologics and small molecules), and geographical location of the service provider.
  • A detailed discussion on various safety features (add-on and integrated devices) installed in recent versions of prefilled syringes and the companies involved in developing and manufacturing such solutions.
  • An informative summary of various guidelines established and issued by major regulatory bodies for the approval of prefilled syringes, across different countries/geographical regions.
  • Brief discussions of currently available specialty syringes, which include prefilled flush syringes, prefilled diluent syringe systems and prefilled contrast agent delivery systems.
  • A case study on companies that are engaged in the manufacturing of autoinjectors, featuring brief profiles of key players in this domain; each profile includes an overview of the firm, and information on its respective product portfolio.
  • Elaborate profiles of prominent prefilled syringe manufacturers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent prefilled syringe component manufacturers, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

Key Topics Covered

1. Preface

2. Executive Summary

3. Introduction to Prefilled Syringes

4. Prefilled Syringes: Market Overview

5. Product Competitiveness Analysis

6. Manufacturers of Prefilled Syringes

7. Needlestick Injuries

8. Regulatory Landscape for Prefilled Syringes

9. Prefilled Syringe Combination Products: Market Overview

10. Key Therapeutic Areas

11. Prefilled Syringes Likely Drug Candidates and Partner Analysis

12. Big Pharma Initiatives: Prefilled Syringe Combination Products and Likely Candidates

13. Specialty Prefilled Syringes

14. Recent Developments and Applications of Prefilled Syringes

15. Market Sizing and Opportunity Analysis

16. Growth Drivers

17. SWOT Analysis

18. Prefilled Syringe Component Manufacturers

19. Fill/Finish Service Providers for Prefilled Syringes

20. Case Study: Autoinjectors

21. Concluding Remarks

22. Interview Transcripts

Companies Featured

  • 3D Medicines
  • Abbott
  • AbbVie
  • Abivax
  • Ablynx
  • Acceleron Pharma
  • Accord Healthcare
  • Activa Brand Products
  • Adamis Pharmaceuticals
  • Adimmune
  • Adocia
  • Advance Pharma Lab
  • Aerpio Therapeutics
  • Affibody
  • Agenus
  • Aguettant
  • Aijex Pharma International
  • Ajinomoto Bio-Pharma Services
  • Akeso Biopharma
  • Akums Drugs & Pharmaceuticals
  • Al Biosciences
  • Alder BioPharmaceuticals
  • Alexion
  • Alfa Corpuscles
  • Alfasigma
  • Alkermes
  • Allergan
  • Alnylam Pharmaceuticals
  • Alphamab Jilin
  • Altor BioScience
  • Alvogen
  • Alvotech
  • Alzheimer's Association
  • AMAG Pharmaceuticals
  • Amega Biotech
  • Amgen
  • AMRI
  • AnaptysBio
  • Andes Biotechnologies
  • Antares Pharma
  • Antev
  • Apellis Pharmaceuticals
  • APL (Apotek Produktion & Laboratorier)
  • Apobiologix
  • Aptar Pharma
  • Aquabiliti
  • Araclon Biotech
  • Archivel Farma
  • Arecor
  • Arrowhead Pharmaceuticals
  • and 300 more!

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900